nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

15. Antihypertonika

verfasst von : Prof. Dr. med. Manfred Anlauf, Prof. Dr. med. Franz Weber

Erschienen in: Arzneiverordnungs-Report 2020

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf einen Blick

Verordnungsprofil In diesem Kapitel zu speziellen Antihypertonika werden neben den Empfehlungen zur antihypertensiven Therapie Alpharezeptorenblocker und zentral wirkende Antisympathotonika sowie Kombinationspräparate von Betarezeptorenblockern und Calciumantagonisten dargestellt.

Trend Auf diese meist älteren Präparate entfällt im Vergleich zu den fünf wichtigen Gruppen der Antihypertonika (Diuretika, Betarezeptorenblocker, ACE-Hemmer, Angiotensinrezeptorantagonisten, Calciumantagonisten) nur ein kleiner Anteil der Verordnungen. Monopräparate eingeschlossen zeigt sich bei den Antihypertonika eine Zunahme der Verordnungen von 3,8 % im Vergleich zum Vorjahr. Sie ist fast ausschließlich eine Folge der Verordnungszunahme von Sartanen um 10,8 %. Von den hier auch besprochenen Vasodilatatoren gegen pulmonale Hypertonie sind in dieser Liste wieder zwei Präparate statt einem im Vorjahr vertreten.

Agarwal R (2017) Implications of blood pressure measurement technique for implementation of systolic blood pressure intervention trial (SPRINT). J Am Heart Assoc 6:e4536. https://doi.org/10.1161/JAHA.116.004536 CrossRef

Anlauf M (2013) Individualisierte Entscheidungen bei der Behandlung der Hypertonie. Arzneiverordn Prax 40:2–4

Anlauf M, Weber F (2005) Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer Berlin (Hrsg) Fortschritt und Fortbildung in der Medizin, Bd. 29. Deutscher Ärzte-Verlag, Köln

Anlauf M, Weber F (2018a) Antihypertonika. In: Schwabe U et al (Hrsg) Arzneiverordnungsreport 2018. Springer, Berlin Heidelberg, S 394

Anlauf M, Weber F (2018b) Blutdruckmessungen zur Hochdruckbekämpfung sollten i. d. R. mit Automaten erfolgen. Dtsch Med Wochenschr 143:59–60PubMed

Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force (2011) ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 123:2434–2506

Arzneimittelkommission der Deutschen Ärzteschaft (2019) Hydrochlorothiazid: Risiko von nichtmelanozytärem Hautkrebs – Empfehlungen der AkdÄ zur Behandlung von Hypertonie und Herzinsuffizienz. Arzneiverordnung in der Praxis 46, Bd. 1–2

Azizi M, Rossignol P, Hulot JS (2019) Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension 74:1075–1083

Barnes H, Brown Z, Burns A, Williams T (2019) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 1:CD12621PubMed

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898PubMed

Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C, HYVET Study Group (2011) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:d7541PubMed

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401PubMed

Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964

Blood Pressure Lowering Treatment Trialists’ Collaboration (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384:591–598

Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D’Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, SPYRAL HTN-OFF MED Pivotal Investigators (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451PubMed

Brown MJ (2011) Personalised medicine for hypertension. BMJ 343:d4697PubMed

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM, British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group (2016) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 4:136–147PubMedPubMedCentral

Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, Qamar A, Pandey A, Olesen TB, Olsen MH, Bhatt DL (2019) Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvz050 PubMedCrossRef

Canadian Hypertension https://guidelines.hypertension.ca/prevention-treatment/uncomplicated-hypertension-goals-of-therapy/. Zugegriffen: 23. Mai 2020

Chow CK, Thakkar Z, Bennett A, Hillis G, Burke M, Usherwood T, Vo K, Rogers K, Atkins E, Webster R, Chou M, Dehbi HM, Salam A, Patel A, Neal B, Peiris D, Krum H, Chalmers J, Nelson M, Reid CM, Woodward M, Hilmer S, Thom S, Rodgers A (2017) Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389:1035–1042PubMed

Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5:659–667PubMed

Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895–906PubMed

Davis BR, Piller LB, Cutler JA, Furberg CC, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2006) Role of diuretics in the prevention of heart failure. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 113:2201–2210PubMed

Desch S, Okon T, Heinemann D, Kulle K, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P (2015) Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 65:1202–1208

Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS (2012) Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59:1124–1131PubMedPubMedCentral

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207PubMed

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967

Falaschetti E, Mindell J, Knott C, Poulter N (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383:1912–1919PubMed

Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, Sineiro E, Castiñeira MC, Callejas PA, Pousa L, Salgado JL, Durán C, Sánchez JJ, Fernández JR, Mojón A, Ayala DE, Hygia Project Investigators (2019) Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz754 PubMedCrossRef

Ho CLB, Breslin M, Doust J, Reid CM, Nelson MR (2018) Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study. BMJ Open 8(3):e17723. https://doi.org/10.1136/bmjopen-2017-017723 CrossRef

Hopkins W, Rubin LJ (2020) Treatment of pulmonary hypertension in adults. https://www.uptodate.com/contents/treatment-of-pulmonary-hypertension-in-adults

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K, Weber MA, Bakris GL, Dahlöf B (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428PubMed

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520PubMed

Khan NA, Rabkin SW, Zhao Y et al (2018) Effect of lowering diastolic pressure in patients with and without cardiovascular disease: analysis of the SPRINT (systolic blood pressure intervention trial). Hypertension 71:840–847PubMed

Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014) Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230

Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, SHEP Collaborative Research Group (2005) Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29–35PubMed

Krieger EM, Drager LF, Giorgi DMA et al (2018) Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 71:681–690PubMed

Lindholm LH, Carlberg B, Samuelsson O (2005) Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553

Malik AH, Shetty S, Kar K, Accaoui RE (2019) Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. J Geriatr Cardiol 16(3):291–297PubMedPubMedCentral

Mancia G, Corrao G (2018) Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Italy. Circulation 137:889–890PubMed

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Chairpersons and Section Coordinators of the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH), European Society of Cardiology (ESC) (2014) Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens 32:1551–1552PubMed

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O (2017) Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Chest 151:106–118PubMed

Middeke M, Lemmer B, Kreutz R, Schrader J, Holzgreve H (2020) Antihypertensiva nicht generell abends nehmen. MMW Fortschr Med 162:34–36PubMed

National Institute for Health and Care Excellence (2019) Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#starting-antihypertensive-drug-treatment. Zugegriffen: 23. Mai 2020

Neuhauser H, Diederichs C, Boeing H, Felix SB, Jünger C, Lorbeer R, Meisinger C, Peters A, Völzke H, Weikert C, Wild P, Dörr M (2016) Bluthochdruck in Deutschland – Daten aus sieben bevölkerungsbasierten epidemiologischen Studien (1994–2012). Dtsch Arztebl Int 113:809–815PubMedPubMedCentral

Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, Agarwal MA, Sharma KH, Mathur SL, Kumbla MM (2016) Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 67:379–389PubMed

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818PubMed

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383:1899–1911PubMedPubMedCentral

Rothwell PM, Coull AJ, Silver LE et al (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366:1773–1783PubMed

Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010a) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375:895–905PubMed

Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators (2010b) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469–480PubMed

Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110–1117PubMed

Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A (2019) Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1567–1573PubMed

Sexton DJ, Canney M, O’Connell MDL, Moore P, Little MA, O’Seaghdha CM, Kenny RA (2017) Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med 177:1385–1387PubMedPubMedCentral

Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ (2018) Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 178:1626–1634PubMedPubMedCentral

Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ (2014) Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64:588–597PubMedPubMedCentral

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G (2018) Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS ONE 13(3):e193226. https://doi.org/10.1371/journal.pone.0193226 CrossRef

Staessen JA, Birkenhäger WH (2005) Evidence that new antihypertensives are superior to older drugs. Lancet 366:869–871PubMed

Staessen JA, Gasowski J, Wang Lj G, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355:865–872

Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 394:1816–1826PubMed

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981–2997

The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood pressure control. N Engl J Med 373:2103–2116PubMedCentral

The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH), The European Society of Cardiology (ESC) (2018) 2018 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 36:1953–2041

Thomopoulosa C, Paratib G, Zanchettid A (2017) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overviewand meta-analyses of randomized trials. J Hypertens 35:2138–2149

Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T (2018) Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc 93:409–418PubMed

Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963–969PubMed

Vidal-Petiot E, Greenlaw N, Ford I et al (2018) Relationships between components of blood pressure and cardiovascular events in patients with stable coronary artery disease and hypertension. Hypertension 71:168–176PubMed

Weber F, Anlauf M (2014) Treatment resistant hypertension – investigation and conservative management. Dtsch Arztebl Int 111:425–431PubMedPubMedCentral

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison-Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13–e115

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society Studies Group (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068PubMedPubMedCentral

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ, British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group (2018) Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6:464–475PubMedPubMedCentral

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA 315:2673–2682PubMedPubMedCentral

Wiysonge CS, Opie LH (2013) β-Blockers as initial therapy for hypertension. JAMA 310:1851–1852PubMed

Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, Liu K, Greenland P, Lloyd-Jones DM (2015) Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol 65:327–335PubMedPubMedCentral

Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999) Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522–1530PubMedPubMedCentral

Titel: Antihypertonika
verfasst von: Prof. Dr. med. Manfred Anlauf
Prof. Dr. med. Franz Weber
Verlag: Springer Berlin Heidelberg
Buch: Arzneiverordnungs-Report 2020
Print ISBN: 978-3-662-62167-7

Electronic ISBN: 978-3-662-62168-4

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-662-62168-4_15

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

15. Antihypertonika

Zusammenfassung

Auf einen Blick

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Auf einen Blick

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin